COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus to Acquire Surface Oncology

16 Jun 2023 07:01:00 By Nasdaq GlobeNewswire

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

05 Jun 2023 17:30:00 By Nasdaq GlobeNewswire

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

01 Jun 2023 08:33:07 By Nasdaq GlobeNewswire

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

01 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

22 May 2023 08:30:00 By Nasdaq GlobeNewswire

Coherus Prices Public Offering of Common Stock

16 May 2023 06:50:00 By Nasdaq GlobeNewswire

Coherus Announces Proposed Public Offering of Common Stock

15 May 2023 16:01:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

08 May 2023 16:05:02 By Nasdaq GlobeNewswire

Coherus BioSciences to Present at Upcoming Investor Conferences in May

04 May 2023 16:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

01 May 2023 16:07:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

27 Apr 2023 08:05:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results

06 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

FDA Approves UDENYCA® Autoinjector

06 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Present at Upcoming Investor Conferences in March

01 Mar 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

28 Feb 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

15 Feb 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

13 Feb 2023 08:25:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

03 Feb 2023 17:30:09 By Nasdaq GlobeNewswire

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

09 Jan 2023 08:20:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:01:00 By Nasdaq GlobeNewswire